Aprea Therapeutics (APRE) Short Interest Ratio & Short Volume → Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (From Behind the Markets) (Ad) Free APRE Stock Alerts $5.14 -0.04 (-0.77%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Aprea Therapeutics Short Interest DataCurrent Short Volume96,200 sharesPrevious Short Volume105,800 sharesChange Vs. Previous Month-9.07%Dollar Volume Sold Short$570,466.00Short Interest Ratio / Days to Cover2.9Last Record DateApril 15, 2024Outstanding Shares5,430,000 sharesFloat Size4,790,000 sharesShort Percent of Float2.01%Today's Trading Volume3,818 sharesAverage Trading Volume26,834 sharesToday's Volume Vs. Average14% Short Selling Aprea Therapeutics ? Sign up to receive the latest short interest report for Aprea Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAPRE Short Interest Over TimeAPRE Days to Cover Over TimeAPRE Percentage of Float Shorted Over Time Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> Aprea Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202496,200 shares $570,466.00 -9.1%2.0%2.9 $5.93 3/31/2024105,800 shares $707,802.00 -9.7%2.4%3.1 $6.69 3/15/2024117,100 shares $724,849.00 +66.8%3.8%3.3 $6.19 2/29/202470,200 shares $593,892.00 -11.6%2.2%2.1 $8.46 2/15/202479,400 shares $450,992.00 -20.5%2.5%5.6 $5.68 1/31/202499,900 shares $516,483.00 -17.0%3.2%7.6 $5.17 Get the Latest News and Ratings for APRE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024120,300 shares $671,274.00 +5.7%3.8%10.7 $5.58 12/31/2023113,800 shares $534,860.00 -1.6%3.6%10.4 $4.70 12/15/2023115,700 shares $444,288.00 -1.6%3.7%11.6 $3.84 11/30/2023117,600 shares $428,064.00 -2.4%3.8%11.4 $3.64 11/15/2023120,500 shares $477,180.00 +4.1%3.9%11.4 $3.96 10/31/2023115,800 shares $394,878.00 -3.3%3.7%9.4 $3.41 10/15/2023119,700 shares $629,622.00 +0.9%3.8%7.5 $5.26 9/30/2023118,600 shares $494,146.90 -5.7%3.8%2.6 $4.17 9/15/2023125,800 shares $503,200.00 -1.3%4.0%2.8 $4.00 8/31/2023127,500 shares $470,475.00 -5.0%4.1%2.8 $3.69 8/15/2023134,200 shares $483,120.00 -9.1%4.3%2.8 $3.60 7/31/2023147,700 shares $457,870.00 +427.5%4.7%3.2 $3.10 7/15/202328,000 shares $87,640.00 +9.4%0.9%0.6 $3.13 6/30/202325,600 shares $80,640.00 +161.2%0.8%2 $3.15 6/15/20239,800 shares $33,418.00 -58.5%0.3%0.7 $3.41 5/31/202323,600 shares $90,860.00 -4.8%0.8%1.8 $3.85 5/15/202324,800 shares $90,768.00 -30.3%0.8%1.7 $3.66 4/30/202335,600 shares $141,154.00 +20.3%1.1%2.3 $3.97 4/15/202329,600 shares $121,360.00 +46.5%0.9%2 $4.10 3/31/202320,200 shares $89,688.00 -56.2%0.6%1.2 $4.44 3/15/202346,100 shares $240,642.00 +31.0%1.4%2.9 $5.22 2/28/202335,200 shares $180,576.00 -3.3%1.0%2.5 $5.13 2/15/202336,400 shares $283,920.00 -94.4%1.9%2.8 $7.80 1/31/2023646,700 shares $324,320.05 -24.3%N/A3 $0.50 1/15/2023854,200 shares $416,507.92 +6.2%N/A4.1 $0.49 12/30/2022804,300 shares $266,223.30 +9.9%N/A5.7 $0.33 12/15/2022731,700 shares $278,046.00 -0.8%N/A5.7 $0.38 11/30/2022737,800 shares $306,187.00 -9.3%N/A5 $0.42 11/15/2022813,300 shares $333,453.00 -8.2%N/A5.4 $0.41 10/31/2022885,700 shares $593,330.43 -9.0%4.5%7.2 $0.67 10/15/2022973,700 shares $740,012.00 +18.5%5.0%7 $0.76 9/30/2022821,800 shares $534,170.00 -6.1%4.2%3.1 $0.65 9/15/2022875,500 shares $773,154.05 +24.7%4.5%1.2 $0.88 8/31/2022701,900 shares $557,378.79 +3.1%3.6%1 $0.79Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. APRE Short Interest - Frequently Asked Questions What is Aprea Therapeutics' current short interest? Short interest is the volume of Aprea Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 96,200 shares of APRE short. 2.01% of Aprea Therapeutics' shares are currently sold short. Learn More on Aprea Therapeutics' current short interest. What is a good short interest ratio for Aprea Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APRE shares currently have a short interest ratio of 3.0. Learn More on Aprea Therapeutics's short interest ratio. Which institutional investors are shorting Aprea Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aprea Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Aprea Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.01% of Aprea Therapeutics' floating shares are currently sold short. Is Aprea Therapeutics' short interest increasing or decreasing? Aprea Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 96,200 shares, a drop of 9.1% from the previous total of 105,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Aprea Therapeutics' float size? Aprea Therapeutics currently has issued a total of 5,430,000 shares. Some of Aprea Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aprea Therapeutics currently has a public float of 4,790,000 shares. How does Aprea Therapeutics' short interest compare to its competitors? 2.01% of Aprea Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Aprea Therapeutics: Acasti Pharma Inc. (0.06%), Unity Biotechnology, Inc. (1.99%), Enlivex Therapeutics Ltd. (1.50%), Lipocine Inc. (5.41%), Biora Therapeutics, Inc. (4.33%), NRx Pharmaceuticals, Inc. (6.69%), Theratechnologies Inc. (0.13%), Forte Biosciences, Inc. (0.09%), Iterum Therapeutics plc (7.50%), Oncternal Therapeutics, Inc. (0.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Aprea Therapeutics stock? Short selling APRE is an investing strategy that aims to generate trading profit from Aprea Therapeutics as its price is falling. APRE shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Aprea Therapeutics? A short squeeze for Aprea Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APRE, which in turn drives the price of the stock up even further. How often is Aprea Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APRE, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Acasti Pharma Short Interest Data Unity Biotechnology Short Interest Data Enlivex Therapeutics Short Interest Data Lipocine Short Interest Data Biora Therapeutics Short Interest Data NRx Pharmaceuticals Short Interest Data Theratechnologies Short Interest Data Forte Biosciences Short Interest Data Iterum Therapeutics Short Interest Data Oncternal Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APRE) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe AI Stock that’s Disrupting Every IndustryStockEarnings